ICON plc | Clinical Research Organisation (CRO) for Drug Development

Leveraging historical data for use in rare disease trials

Understanding the Bayesian and Frequentist approaches.

ICER’s impact on payer decision making

Results of ICON’s third annual survey.

Mitigating the impact of COVID-19 on cardiovascular trials

Ensure patient safety and trial integrity during a global pandemic.

Dynamics of patient centricity in clinical research

Exploring the patient dynamic from different perspectives.

Webinars

Engaging physicians to support and increase clinical research activity

19 January, 2021. Register now.

Financial Times Digital Dialogues: Building resilience in pharma R&D by decentralising and digitising

FT Digital Dialogues: Building resilience in pharma R&D by decentralising and digitising

3 February 2021. Register today.

On-demand webinars

Visit our webinar channel to access our library of archived webinars.

Featured Services

COVID-19 clinical operations

Keeping your clinical trial on track in an evolving environment.

Site & Patient Solutions

Transforming recruitment through patient-centric trials and real-world, real-time data.

Biotech

ICON provides full service outsourcing and flexible support for biotech specific needs such as due diligence and asset valuation.

Functional Resourcing

From recruitment of a single clinical professional to managing entire global functions.

Biosimilars

ICON can support product design, development and registration, regulatory support and commercialisation of Biosimilars.

Increasing Site and Patient Compliance

FIRECREST: Digital solutions to increase efficiency in clinical trials by driving site performance.

ICON Insights

18 January 2021

Data capture: The benefits and evolution of eCOA

As the demand for improving patient safety in clinical trials continues to rise, so will the use of technology as a way to better capture data and enhance clinical outcome assessments (COAs).

12 January 2021

Risk, vigilance, and remediation under IVDR

The In Vitro Diagnostics Regulation (IVDR) — which goes into effect on May 26, 2022 — will have a lasting impact on the entire in vitro diagnostics (IVD) lifecycle, from development through clinical investigations and regulatory approval.

08 January 2021

Managing COVID disruptions within IVDR timelines

The COVID-19 pandemic has greatly impacted the IVD industry, including travel and social distancing restrictions, creating hassles and stalling NB designation processes.

06 January 2021

Exploring the benefits of biotech partnerships

The biotechnology sector is leading the way in developing innovative therapies that will address the unmet needs of many challenging diseases.

04 January 2021

Cancer research post-COVID-19

The COVID-19 pandemic has been a catalyst for change in cancer research, forcing a shift towards remote monitoring, virtual arms and other uses of digital tools as global lockdowns reduce the ability of patients to go to clinics.

27 April 2020

The shifting diagnostics regulatory landscape amid COVID-19

For IVD manufacturers, the emergence of a novel virus is challenging as the detection of such viruses require quickly developed, novel diagnostic solutions.

Coronavirus Observatory

Aggregated news, stats and social media on covid-19 clinical trials. Visit Observatory

Services

Sectors

Therapeutics

Innovation

Insights

News & Events

About ICON

The evolution of HIV treatments

The IVDR journey

Agile Clinical Monitoring

Challenges and opportunities in traumatic brain injury clinical trials